ConstipationTENSNCT05946967
Colon Transit Study for Chronic Constipation Assessment and Therapy by Biofeedback With and Without TENS
A study testing Biofeedback with TENS and Biofeedback only in people with Constipation, run by Sanjay Gandhi Postgraduate Institute of Medical Sciences.
Trial summary
One of the most challenging functional gastrointestinal illnesses (FGID) to manage is constipation, which is a widespread issue. The fact that constipation can be caused by a variety of conditions, including slow colon transit, faecal evacuation disorder, or a combination of both slow colon transit and faecal… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Constipation
- What is being tested?
- Biofeedback with TENS and Biofeedback only
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 20 Jul 2023to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- i) Patient with refractory chronic constipation ii) 18-65 years of age
Who cannot join
- i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) <18 years of age iv) >65 years of age
About this study
Official title: Colon Transit Study for Assessment of Chronic Constipation and Therapy Directed Against Fecal Evacuation Disorder by Biofeedback With or Without Transcutaneous Electrical Stimulation of Posterior Tibial Nerve
One of the most challenging functional gastrointestinal illnesses (FGID) to manage is constipation, which is a widespread issue. The fact that constipation can be caused by a variety of conditions, including slow colon transit, faecal evacuation disorder, or a combination of both slow colon transit and faecal evacuation disorder, is one of the main reasons it is challenging to treat. Treatment options vary based on the pathogenetic mechanism; for instance, biofeedback, botulinum toxin injections in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) are required to treat faecal evacuation problem. On the other hand, prucalopride and other colokinetic drugs as well as drugs that promote high amplitude propagating contractions, including bisacodyl and sodium pyrosulphate, are used to treat slow transit constipation. Sometimes faecal evacuation disorders that inhibit the evacuation of the transit markers can cause slow colon transit times; these secondary sluggish colon transit times have been shown to improve with biofeedback therapy alone. Even though the causes of faecal evacuation disorders are not fully understood, it is known that abnormal neuromuscular function is the result. A few workers have stimulated the posterior tibial nerve, another sacral plexus branch, non-invasively with TENS. Studies on the use of biofeedback in the treatment of patients with faecal evacuation problems are lacking. Accordingly, we wish to undertake a prospective study with following aims: (i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time). (ii) To assess the efficacy of pathogenesisdirected therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder. (iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.
Read the detailed description
Introduction Constipation is a common problem and one of the most difficult functional gastrointestinal diseases (FGID) to treat. An Asian survey showed that among patients with FGID, constipation patients are most dissatisfied with treatment . One of the major reasons why constipation is difficult to treat is because of the fact that constipation may result from multiple factors like slow colon transit, fecal evacuation disorder, or a combination of both slow colon transit and fecal evacuation disorder . Until and unless the exact cause is identified, the empirical treatment with laxatives does not work. Treatment varies depending upon the pathogenetic mechanism, for example, fecal evacuation disorder needs to be treated with biofeedback , botulinum toxin injection in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) . On the other hand, slow transit constipation is treated with colokinetic agents such as prucalopride and agents stimulating high amplitude propagated contractions such as bisacodyl and sodium pyrosulphate. Sometimes colon transit time may be slow secondary to fecal evacuation disorder mitigating evacuation of the transit markers; such secondary slow colon transit has been shown to improve with biofeedback therapy alone.
Fecal evacuation disorders are diagnosed with anorectal manometry, balloon expulsion test, and barium or magnetic resonance imaging defecography. On the other hand, slow transit constipation is diagnosed by radio-nuclide colon transit study, a colon transit study using radio-opaque markers and smart pills, etc. Since these investigations are not widely available, it becomes difficult to detect the mechanism of constipation in practice by many physicians and gastroenterologists. Two tests that can be easily performed in office practice by most physicians and gastroenterologists include: (i) balloon expulsion test, (ii) colon transit time (CTT) by opaque markers. Detecting these pathophysiological mechanisms of chronic constipation is expected to provide personalized therapy for these patients.
Though mechanisms of fecal evacuation disorders are poorly understood, yet it is known that it results from abnormal neuromuscular function resulting in lack of increase in intra-rectal pressure during attempted defecation and failure of relaxation of pelvic floor muscles. This led to some workers to treat these patients with sacral nerve stimulation, which is primarily used to treat fecal incontinence. However, sacral nerve stimulation is quite invasive, requires major surgical procedure and is associated with multiple complications, including infection. A few workers have used non-invasive TENS to stimulate posterior tibial nerve, which is also a branch of sacral plexus. However, there is lack of studies to treat patients with fecal evacuation disorders with or without biofeedback, which is considered, the first-line therapy for fecal evacuation disorder. Accordingly, we hypothesized that, (i) the office-based investigation such as colon transit study using radio-opaque markers will be useful to diagnose fecal evacuation disorder, which will be able to direct further therapy, (ii) biofeedback with TENS for posterior tibial nerve will be superior to biofeedback alone to treat fecal evacuation disorder, and (iii) successful treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve will improve colon transit as assessed by radio-opaque marker study.
Accordingly, we wish to undertake a prospective study with following aims:
(i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time).
(ii) To assess the efficacy of pathogenesis-directed therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder.
(iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.
Methodology
Inclusion criteria:
- Patient with refractory chronic constipation ii) >18 years of age Exclusion criteria i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) <18 years of age
Fifty patients with chronic constipation will undergo the below-mentioned tests as per standardized protocol. It is important to mention here that all these tests are standard of care for these patients. The tests are: (i) anorectal manometry, (ii) balloon expulsion, (iii) colon transit study by an indigenous radio-opaque marker according to the standard of care, and (iv) defecography (either barium or magnetic resonance imaging).
The diagnostic criteria for fecal evacuation disorder will be as follows: positive result in 2 of the following tests - a) anorectal manometry with defecation index of <1.4, b) abnormal balloon expulsion test, c) abnormal defecography.
The ability of CTT to diagnose fecal evacuation disorder and slow transit constipation among these subjects will be assessed. Patients with fecal evacuation disorders diagnosed as above will be subjected to daily biofeedback with one group receiving TENS daily and the other group receiving sham stimulations. These treatments will be given for 10 days. The treatment group shall be decided based upon the understanding with patients and mutual decision of the doctor and the patient. Standard treatment of stimulative laxatives will be given to patients with bloating and ispaghula husk to patients without bloating.
No patient will have to pay for biofeedback and TENS. The other tests (anorectal manometry, balloon expulsion, colon transit study, and defecography) are standard of care for patients with constipation. Follow up will be done at 1 month and 3 months as described in figure 2.
Outcome measures i) Constipation severity questionnaire will be used to assess the Constipation Scoring System.
ii) Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary.
iii) Dose of laxatives used. iv) After the end of treatment, colon transit study will be repeated to assess its improvement.
- Conditions
- Constipation
- Being tested
- Biofeedback with TENS, Biofeedback only
- Keywords
- CTT, IBS-C, Functional-constipation
- Medical subject headings
- Constipation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biofeedback with TENSOther
Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
Biofeedback onlyOther
Constipation patients will be given biofeedback treatment only
| Study group | Role | What they receive |
|---|---|---|
| Biofeedback with TENS | Active comparator | Patients with constipation will undergo biofeedback treatment along with transcutaneous electrical stimulation (TENS) Receives: Other: Biofeedback with TENS |
| Biofeedback only | Sham comparator | Patients with constipation will undergo biofeedback treatment only Receives: Other: Biofeedback only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Constipation severity
Constipation severity questionnaire will be used to assess the Constipation Scoring System
Measured: 3 months
Bowel movement assessment
Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary
Measured: 3 months
Treatment effect
After the end of treatment, colon transit study will be repeated to assess its improvement.
Measured: 3 months
Secondary outcomes (1)
Dose of laxatives
Dose of laxatives used will be recorded
Measured: 3 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2023
- Study start20 Jul 2023 (estimated)
- Primary completion30 Sep 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ConstipationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05946967
- Sponsor's protocol ID
- 2023-128-DM-131
- Acronym
- TENS
- Status last verified
- Jul 2023
- First submitted
- 7 Jul 2023
- Last updated
- 14 Jul 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Colon Transit Study for Assessment of Chronic Constipation and Therapy Directed Against Fecal Evacuation Disorder by Biofeedback With or Without Transcutaneous Electrical Stimulation of Posterior Tibial Nerve
- ClinicalTrials.gov ID
- NCT05946967
- Acronym / sponsor ID
- TENS / 2023-128-DM-131
- Conditions
- Constipation
- Keywords
- CTT, IBS-C, Functional-constipation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Sanjay Gandhi Postgraduate Institute of Medical SciencesOther government
- Study start
- 20 Jul 2023 (estimated)
- Primary completion
- 30 Sep 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 14 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
One of the most challenging functional gastrointestinal illnesses (FGID) to manage is constipation, which is a widespread issue. The fact that constipation can be caused by a variety of conditions, including slow colon transit, faecal evacuation disorder, or a combination of both slow colon transit and faecal evacuation disorder, is one of the main reasons it is challenging to treat. Treatment options vary based on the pathogenetic mechanism; for instance, biofeedback, botulinum toxin injections in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) are required to treat faecal evacuation problem. On the other hand, prucalopride and other colokinetic drugs as well as drugs that promote high amplitude propagating contractions, including bisacodyl and sodium pyrosulphate, are used to treat slow transit constipation. Sometimes faecal evacuation disorders that inhibit the evacuation of the transit markers can cause slow colon transit times; these secondary sluggish colon transit times have been shown to improve with biofeedback therapy alone. Even though the causes of faecal evacuation disorders are not fully understood, it is known that abnormal neuromuscular function is the result. A few workers have stimulated the posterior tibial nerve, another sacral plexus branch, non-invasively with TENS. Studies on the use of biofeedback in the treatment of patients with faecal evacuation problems are lacking. Accordingly, we wish to undertake a prospective study with following aims: (i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time). (ii) To assess the efficacy of pathogenesisdirected therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder. (iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.
Detailed description
Introduction Constipation is a common problem and one of the most difficult functional gastrointestinal diseases (FGID) to treat. An Asian survey showed that among patients with FGID, constipation patients are most dissatisfied with treatment . One of the major reasons why constipation is difficult to treat is because of the fact that constipation may result from multiple factors like slow colon transit, fecal evacuation disorder, or a combination of both slow colon transit and fecal evacuation disorder . Until and unless the exact cause is identified, the empirical treatment with laxatives does not work. Treatment varies depending upon the pathogenetic mechanism, for example, fecal evacuation disorder needs to be treated with biofeedback , botulinum toxin injection in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) . On the other hand, slow transit constipation is treated with colokinetic agents such as prucalopride and agents stimulating high amplitude propagated contractions such as bisacodyl and sodium pyrosulphate. Sometimes colon transit time may be slow secondary to fecal evacuation disorder mitigating evacuation of the transit markers; such secondary slow colon transit has been shown to improve with biofeedback therapy alone.
Fecal evacuation disorders are diagnosed with anorectal manometry, balloon expulsion test, and barium or magnetic resonance imaging defecography. On the other hand, slow transit constipation is diagnosed by radio-nuclide colon transit study, a colon transit study using radio-opaque markers and smart pills, etc. Since these investigations are not widely available, it becomes difficult to detect the mechanism of constipation in practice by many physicians and gastroenterologists. Two tests that can be easily performed in office practice by most physicians and gastroenterologists include: (i) balloon expulsion test, (ii) colon transit time (CTT) by opaque markers. Detecting these pathophysiological mechanisms of chronic constipation is expected to provide personalized therapy for these patients.
Though mechanisms of fecal evacuation disorders are poorly understood, yet it is known that it results from abnormal neuromuscular function resulting in lack of increase in intra-rectal pressure during attempted defecation and failure of relaxation of pelvic floor muscles. This led to some workers to treat these patients with sacral nerve stimulation, which is primarily used to treat fecal incontinence. However, sacral nerve stimulation is quite invasive, requires major surgical procedure and is associated with multiple complications, including infection. A few workers have used non-invasive TENS to stimulate posterior tibial nerve, which is also a branch of sacral plexus. However, there is lack of studies to treat patients with fecal evacuation disorders with or without biofeedback, which is considered, the first-line therapy for fecal evacuation disorder. Accordingly, we hypothesized that, (i) the office-based investigation such as colon transit study using radio-opaque markers will be useful to diagnose fecal evacuation disorder, which will be able to direct further therapy, (ii) biofeedback with TENS for posterior tibial nerve will be superior to biofeedback alone to treat fecal evacuation disorder, and (iii) successful treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve will improve colon transit as assessed by radio-opaque marker study.
Accordingly, we wish to undertake a prospective study with following aims:
(i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time).
(ii) To assess the efficacy of pathogenesis-directed therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder.
(iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.
Methodology
Inclusion criteria:
- Patient with refractory chronic constipation ii) >18 years of age Exclusion criteria i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) <18 years of age
Fifty patients with chronic constipation will undergo the below-mentioned tests as per standardized protocol. It is important to mention here that all these tests are standard of care for these patients. The tests are: (i) anorectal manometry, (ii) balloon expulsion, (iii) colon transit study by an indigenous radio-opaque marker according to the standard of care, and (iv) defecography (either barium or magnetic resonance imaging).
The diagnostic criteria for fecal evacuation disorder will be as follows: positive result in 2 of the following tests - a) anorectal manometry with defecation index of <1.4, b) abnormal balloon expulsion test, c) abnormal defecography.
The ability of CTT to diagnose fecal evacuation disorder and slow transit constipation among these subjects will be assessed. Patients with fecal evacuation disorders diagnosed as above will be subjected to daily biofeedback with one group receiving TENS daily and the other group receiving sham stimulations. These treatments will be given for 10 days. The treatment group shall be decided based upon the understanding with patients and mutual decision of the doctor and the patient. Standard treatment of stimulative laxatives will be given to patients with bloating and ispaghula husk to patients without bloating.
No patient will have to pay for biofeedback and TENS. The other tests (anorectal manometry, balloon expulsion, colon transit study, and defecography) are standard of care for patients with constipation. Follow up will be done at 1 month and 3 months as described in figure 2.
Outcome measures i) Constipation severity questionnaire will be used to assess the Constipation Scoring System.
ii) Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary.
iii) Dose of laxatives used. iv) After the end of treatment, colon transit study will be repeated to assess its improvement.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Biofeedback with TENS | Active comparator | Other: Biofeedback with TENSPatients with constipation will undergo biofeedback treatment along with transcutaneous electrical stimulation (TENS) |
| Biofeedback only | Sham comparator | Other: Biofeedback onlyPatients with constipation will undergo biofeedback treatment only |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- i) Patient with refractory chronic constipation ii) 18-65 years of age
Key exclusion criteria (1 listed)
- i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) <18 years of age iv) >65 years of age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biofeedback with TENSConstipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve | Other | Biofeedback with TENS |
| Biofeedback onlyConstipation patients will be given biofeedback treatment only | Other | Biofeedback only |
Primary outcome
Constipation severity
Time frame: 3 months
Constipation severity questionnaire will be used to assess the Constipation Scoring System
Bowel movement assessment
Time frame: 3 months
Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary
Treatment effect
Time frame: 3 months
After the end of treatment, colon transit study will be repeated to assess its improvement.
1 secondary outcome
Dose of laxatives
Time frame: 3 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2023.
Related trials for Constipation
Recruiting
Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence
Faecal Incontinence, Chronic Constipation
Active, not recruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Functional Constipation (FC)
Not yet recruiting
Acupuncture Combined With Transcutaneous Electrical Acupoint Stimulation for Constipation-Predominant Irritable Bowel Syndrome With Anxiety State
IBS, Constipation Predominant, Anxiety State
Not yet recruitingPhase 3
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
Bloating, Rifaximin
Recruiting
Effect of Abdominal Massage Training Provided to Caregivers on Constipation Management
Constipation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Biofeedback with TENS and Biofeedback only in people with Constipation, run by Sanjay Gandhi Postgraduate Institute of Medical Sciences.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Constipation severity (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2023; AzTrials last refreshed its copy on 4 Nov 2026.